Interleukin-6 Deficiency Fails to Prevent Chronic Rejection After Aortic Allografts in Apolipoprotein E-Deficient Mice

Journal of Heart and Lung Transplantation

Volumn 28, Issue 1, 2009, Pages 85-92

  Yacoub Youssef, Houda ^a,b   Blaes, Nelly ^a,b   Calise, Denis ^b   Thiers, Jean Claude ^a,b   Therville, Nicole ^a,b   Benoist, Hervé ^a,b   Ségui, Bruno ^a,b   Al Saati, Talal ^c   Thomsen, Mogens ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Parc Scientifique de Luminy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; APOLIPOPROTEIN E; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA GRAFT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GRAFT REJECTION; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; AORTA; APOLIPOPROTEINS E; GRAFT REJECTION; INTERLEUKIN-6; ISOANTIBODIES; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; TRANSPLANTATION, HOMOLOGOUS; VASCULAR RESISTANCE;

EID: 58149165171     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.06.012     Document Type: Article

References (51)

1. Billingham M.E. Histopathology of graft coronary disease. J Heart Lung Transplant 11 (1992) S38-S44
2. Rossen R.D., Butler W.T., Reisberg M.A., et al. Immunofluorescent localization of human immunoglobulin in tissues from cardiac allograft recipients. J Immunol 106 (1971) 171-180
3. Tilney N.L., Garovoy M.R., Busch G.J., Strom T.B., Graves M.J., and Carpenter C.B. Rejected human renal allografts: recovery and characteristics of infiltrating cells and antibody. Transplantation 28 (1979) 421-426
4. Shi C., Lee W.S., He Q., et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 93 (1996) 4051-4056
5. Uehara S., Chase C.M., Kitchens W.H., et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 175 (2005) 3424-3430
6. Libby P., and Pober J.S. Chronic rejection. Immunity 14 (2001) 387-397
7. Avery R.K. Cardiac-allograft vasculopathy. N Engl J Med 349 (2003) 829-830
8. Mitchell R.N., and Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 100 (2007) 967-978
9. Kanda T., and Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 45 (2004) 183-193
10. Cueto-Manzano A.M., Morales-Buenrostro L.E., Gonzalez-Espinoza L., et al. Markers of inflammation before and after renal transplantation. Transplantation 80 (2005) 47-51
11. Densem C.G., Ray M., Hutchinson I.V., Yonan N., and Brooks N.H. Interleukin-6 polymorphism: a genetic risk factor for cardiac transplant related coronary vasculopathy?. J Heart Lung Transplant 24 (2005) 559-565
12. Plenz G., Eschert H., Erren M., et al. The interleukin-6/interleukin-6-receptor system is activated in donor hearts. J Am Coll Cardiol 39 (2002) 1508-1512
13. Deng M.C., Plenz G., Labarrere C., et al. The role of IL6 cytokines in acute cardiac allograft rejection. Transpl Immunol 9 (2002) 115-120
14. Boratynska M., Klinger M., Szyber P., Patrzalek D., and Polak K. Interleukin-6 in chronic renal allograft rejection: influence of nonimmunologic risk factors. Transplant Proc 33 (2001) 1215-1217
15. Sadeghi M., Daniel V., Wiesel M., Hergesell O., and Opelz G. High urine sIL-6R as a predictor of late graft failure in renal transplant recipients. Transplantation 76 (2003) 1190-1194
16. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23 (2005) 1-21
17. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 8 (1990) 253-278
18. Tilg H., Dinarello C.A., and Mier J.W. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18 (1997) 428-432
19. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., and Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101 (1998) 311-320
20. Paul W.E., and Seder R.A. Lymphocyte responses and cytokines. Cell 76 (1994) 241-251
21. Diehl S., and Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39 (2002) 531-536
22. Hricik D.E., Mayes J.T., and Schulak J.A. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis 18 (1991) 353-358
23. Maluf D.G., Mas V.R., Archer K.J., et al. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment. Transplantation 80 (2005) 1705-1711
24. Perrault L.P., Mahlberg F., Breugnot C., et al. Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. Arterioscler Thromb Vasc Biol 20 (2000) 728-736
25. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
26. Elhage R., Clamens S., Besnard S., et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 156 (2001) 315-320
27. Huber S.A., Sakkinen P., Conze D., Hardin N., and Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19 (1999) 2364-2367
28. Schieffer B., Selle T., Hilfiker A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110 (2004) 3493-3500
29. Dambrin C., Calise D., Pieraggi M.T., Thiers J.C., and Thomsen M. Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis. J Heart Lung Transplant 18 (1999) 946-951
30. Thomsen M., Dambrin C., Uro-Coste E., et al. An orthotopic aortic graft mouse model to study the immunopathology of chronic vascular rejection. Transplant Proc 34 (2002) 2833-2835
31. Armstrong A.T., Strauch A.R., Starling R.C., Sedmak D.D., and Orosz C.G. Morphometric analysis of neointimal formation in murine cardiac grafts: III. Dissociation of intestitial fibrosis from neointimal formation. Transplantation 64 (1997) 1198-1202
32. Piccotti J.R., Li K., Chan S.Y., Eichwald E.J., and Bishop D.K. Cytokine regulation of chronic cardiac allograft rejection: evidence against a role for Th1 in the disease process. Transplantation 67 (1999) 1548-1555
33. Shirwan H. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role?. Transplantation 68 (1999) 715-726
34. Bickerstaff A.A., Wang J.J., Pelletier R.P., and Orosz C.G. Murine renal allografts: spontaneous acceptance is associated with regulated T cell-mediated immunity. J Immunol 167 (2001) 4821-4827
35. Kitagawa-Sakakida S., Fukushima N., Sawa Y., et al. Microarray-based gene expression profiling of retransplanted rat cardiac allografts that develop cardiac allograft vasculopathy. J Heart Lung Transplant 24 (2005) 2068-2074
36. Plissonnier D., Nochy D., Poncet P., et al. Sequential immunological targeting of chronic experimental arterial allograft. Transplantation 60 (1995) 414-424
37. Andriambeloson E., Cannet C., Pally C., et al. Transplantation-induced functional/morphological changes in rat aorta allografts differ from those in arteries of rat kidney allografts. Am J Transplant 4 (2004) 188-195
38. Yacoub-Youssef H., Marcheix B., Calise D., et al. Chronic vascular rejection: histologic comparison between two murine experimental models. Transplant Proc 37 (2005) 2886-2887
39. Baddoura F.K., Nasr I.W., Wrobel B., Li Q., Ruddle N.H., and Lakkis F.G. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 5 (2005) 510-516
40. Orosz C.G. Considerations regarding the contributions of B cells to chronic allograft rejection in experimental animal models. J Heart Lung Transplant 19 (2000) 634-637
41. Soleimani B., Katopodis A., Wieczorek G., George A.J., Hornick P.I., and Heusser C. Smooth muscle cell proliferation but not neointimal formation is dependent on alloantibody in a murine model of intimal hyperplasia. Clin Exp Immunol 146 (2006) 509-517
42. Dietrich H., Hu Y., Zou Y., et al. Rapid development of vein graft atheroma in ApoE-deficient mice. Am J Pathol 157 (2000) 659-669
43. Moos M.P., John N., Grabner R., et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25 (2005) 2386-2391
44. Ali K., Middleton M., Pure E., and Rader D.J. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97 (2005) 922-927
45. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
46. Korn T., Bettelli E., Gao W., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
47. Tang J.L., Subbotin V.M., Antonysamy M.A., Troutt A.B., Rao A.S., and Thomson A.W. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 72 (2001) 348-350
48. Legare J.F., Issekutz T., Lee T.D., and Hirsch G. CD8+ T lymphocytes mediate destruction of the vascular media in a model of chronic rejection. Am J Pathol 157 (2000) 859-865
49. Liang Y., Christopher K., Finn P.W., Colson Y.L., and Perkins D.L. Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation. Transplantation 84 (2007) 771-777
50. Pawlik A., Domanski L., Rozanski J., et al. The cytokine gene polymorphisms in patients with chronic kidney graft rejection. Transpl Immunol 14 (2005) 49-52
51. Perez-Villa F., Benito B., Llancaqueo M., Cuppoletti A., and Roig E. Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc 38 (2006) 3012-3015